Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab Combination Therapies in mCRPC (KEYNOTE-365)
NCT02861573Phase 2Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Nov 2016
- Primary completion
- Oct 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
01
Overview
A Phase 2 trial of pembrolizumab in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Merck & Co.. Started Nov 2016; status: active, not recruiting.
02
Drugs
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT02861573.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02861573.